Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 19/20 | 0.64 |
| ▸ | MC3R | P41968 | 7/20 | 0.64 |
| ▸ | MC5R | P33032 | 7/20 | 0.64 |
| ▸ | MC1R | Q01726 | 6/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | PRCP | P42785 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327071 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29327068 | 1.00 | MC4R (0.64) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29327061 | 0.95 | MC4R (0.69) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29327062 | 0.95 | MC4R (0.69) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29326983 | 0.95 | MC4R (0.69) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29327081 | 0.91 | MC4R (0.70) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29327078 | 0.91 | MC4R (0.70) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29326988 | 0.91 | MC4R (0.70) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29326985 | 0.89 | MC4R (0.68) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL29327066 | 0.89 | MC4R (0.68) | MC4RMC3RMC5RMC1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | AQP3, SLC6A7, ABCG2 | MC4R 2367/4885MC3R 1834/4885MC5R 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.